Inquiry Basket
| Catalog | Product Name | CAS Number |
|---|---|---|
| BADC-01467 | Lys-Nε-SPDB-DM4 | 1280215-91-9 |
| Lys-Nε-SPDB-DM4 is a drug-linker conjugate consisting of the potent tubulin inhibitor DM4 and the linker Lys-Nε-SPDB for the preparation of antibody-drug conjugates (ADCs). | Inquiry | |
| BADC-01468 | DM1-PEG4-DBCO | |
| DM1-(PEG)4-DBCO is a drug conjugate (ADC) consisting of the tubulin inhibitor DM1 and the linker DBCO-PEG4-Ahx. Mertansin (DM1), a tubulin inhibitor, is an antibody-conjugated maytansine developed to overcome the systemic toxicity associated with maytansine and enhance tumor-specific delivery. | Inquiry | |
| BADC-01469 | Sulfo-SPDB-DGN462 | |
| Sulfo-SPDB-DGN462 is an extraordinary biomedicine chemical, exhibits unrivaled capabilities in combatting a multitude of diseases and ailments. Its mesmerizing prowess as an unparalleled inhibitor against a specific cadre of enzymes renders it immensely efficacious in curbing the malignant proliferation of cancer cells, subduing infirmities born out of inflammation, and addressing maladies pertaining to the neural system. | Inquiry | |
| BADC-01470 | MC-Val-Cit-PAB-dimethylDNA31 | 1639352-06-9 |
| MC-Val-Cit-PAB-dimethylDNA31 has a bioreversible linkage based on a quaternary ammonium for targeted delivery and it can improve pharmacokinetics and the therapeutic index. MC-Val-Cit-PAB-dimethylDNA31 is used for the antibody-drug conjugates (ADC) that are effective and stable in vitro and in vivo to treat various diseases or disorders. | Inquiry | |
| BADC-01471 | TLR7/8 agonist 4 hydroxy-PEG10-acid | 2388520-17-8 |
| TLR7/8 agonist 4 hydroxy-PEG10-acid (compound 9) is part of an antibody-drug conjugate composed of TLR7/8 activator TLR7/8 agonist 4 (HY-139018) and degradable ADC linker hydroxy-PEG10- acid (HY-133307) concatenated. | Inquiry | |
| BADC-01472 | MAC-VC-PABC-ST7612AA1 | |
| MAC-VC-PABC-ST7612AA1 is part of Antibody Drug Conjugate ADCs with HDAC inhibitor payload and linker for antitumor activity. | Inquiry | |
| BADC-01473 | MC-VC-PABC-SP 141 | |
| MC-VC-PABC-SP 141 is part of an antibody-drug conjugate, which is composed of a potent MDM2 inhibitor SP 141 and a degradable ADC linker MC-VC-PABC. | Inquiry | |
| BADC-01474 | PSMA-ALB-56 | 2306049-48-7 |
| PSMA-ALB-56 is a PSMA-targeting radioligand consisting of a glutamate-urea PSMA-binding entity and an albumin conjugate. | Inquiry | |
| BADC-01475 | N3-PEG8-Phe-Lys-PABC-Gefitinib | |
| N3-PEG8-Phe-Lys-PABC-Gefitinib is composed of anticancer drug Gefitinib (an oral active inhibitor) and degradable ADC linker N3-PEG8-Phe-Lys-PABC. | Inquiry | |
| BADC-01476 | FCHFHS-ST7612AA1 | |
| FCHFHS-ST7612AA1 is part of Antibody Drug Conjugate ADCs with HDAC inhibitor payload and linker for antitumor activity. | Inquiry | |
| BADC-01536 | DBCO-Peg4-VC-PAB-MMAE | 2129164-91-4 |
| DBCO-Peg4-VC-PAB-MMAE is a cytotoxin and linker conjugate widely used in ADCs. | Inquiry | |
| BADC-01626 | CL2A-SN-38 DCA | |
| CL2A-SN-38 is a drug-linker conjugate composed of a potent DNA Topoisomerase I inhibitor SN-38 and a linker CL2A to make antibody-drug conjugate (ADC). It has significant specific antitumor effects on a variety of human solid tumor types. | Inquiry |
